Eurofins Central Laboratory is a member of Eurofins BioPharma Services, a division of Eurofins Scientific, (hereinafter sometimes “Eurofins” or “the Group”). As a member of the Group, we are pleased to release to you our Q3 2019 earnings. Over the first nine months of 2019, total revenues grew 23.6% to EUR 3,335m vs. EUR 2,698m during the same period last year. Eurofins continues to express strong organic growth of 6.4% reported in Q3 2019. In Western Europe and North America, Eurofins BioPharma Services continued to perform exceptionally, with a double digit organic growth in Q3 2019 thanks to sustained, above market and overall growth as strategic outsourcing remains strong in the biopharmaceutical industry.
Message from the CEO, Dr. Gilles Martin:
“Q3 2019 was a very positive quarter for Eurofins as the Group demonstrated prompt recovery following the June cyber-attack and delivered strong organic growth. This is concrete evidence of our positioning in attractive end markets as well as our ability to leverage our scale as we approach the end of our 2016-2020 strategic investment plan to build a one-of-a-kind global network of state-of-the-art laboratories and bespoke IT solutions aimed at offering a unique outstanding level of service to our customers. We remain confident on our ability to achieve our objectives for this and next year. By the end of 2020, this exceptional investment phase started in 2016 will largely be completed and Eurofins clients should benefit from further improved levels of service from a more efficient network of Eurofins laboratories. This should enable the group to start significantly improving cash flow generation and return on investment from 2021 onwards.”
Eurofins Scientific believes it is the world leader in food, environment and pharmaceutical products testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences and for supporting clinical studies. In addition, Eurofins is a key player in specialty clinical diagnostic testing in Europe and the USA. With about 45,000 staff in more than 800 laboratories across 47 countries, Eurofins offers a portfolio of over 200,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.
The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).
For full Press Release, click here: https://www.eurofins.com/media-centre/press-releases/2019-10-28/